Related Experiment Video
Updated: Aug 13, 2026
09:19
In Vitro Microfluidic Disease Model to Study Whole Blood-Endothelial Interactions and Blood Clot Dynamics in Real-Time
Published on: May 24, 2020
[Hormonal contraception and thromboembolic disease--new epidemiologic data]
1Gynekologicko-porodnická klinika LF MU Brno.
Ceska Gynekologie
|September 25, 2001
Summary
Combined oral contraceptives (COCs) users may have a slightly increased risk of venous thromboembolism (VTE). Studies suggest third-generation COCs might pose a higher VTE risk than second-generation ones, though overall risks remain low.
Area of Science:
- Reproductive Health
- Pharmacovigilance
- Epidemiology
Context:
- Combined oral contraceptives (COCs) are widely used for birth control.
- Concerns exist regarding the association between COC use and venous thromboembolism (VTE).
- Research in the late 1990s focused on comparing VTE risks among different generations of COCs.
Purpose:
- To synthesize findings from studies published between 1996 and 2000 on VTE risk in combined oral contraceptive users.
- To evaluate the evidence for differential VTE risk associated with various progestin formulations in COCs.
Summary:
- Multiple epidemiological studies from 1995-1996 indicated a twofold increased VTE risk in users of third-generation COCs compared to second-generation COCs.
- Methodological criticisms of these studies, including potential biases, were raised but subsequently addressed by further research.
- Subsequent analyses, including a 2000 GRPD study by Jick et al., corroborated the initial findings, suggesting a probable difference in VTE risk based on progestin content.
- Pathophysiological mechanisms supporting these observed differences in risk have also been identified.
Impact:
- The findings suggest a potential difference in VTE risk among users of oral contraceptives containing different progestins.
- Despite the identified differences, the relative risks of VTE associated with COC use are considered low.
- This information is crucial for informed prescribing practices and patient counseling regarding contraceptive choices.
Related Concept Videos
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:22Hormonal Regulation of the Menstrual Cycle
The ovarian cycle regulates endometrial changes throughout a single menstrual cycle via the coordinated action of gonadotrophin-releasing hormone (GnRH) and gonadotrophins.
At puberty, GnRH begins a pulsatile release pattern, which triggers the anterior pituitary gland to secrete follicle-stimulating hormone (FSH) and luteinizing hormone (LH). The frequency and amplitude of GnRH pulses vary across the menstrual cycle, with faster pulses favoring LH release and slower pulses favoring FSH release.
At puberty, GnRH begins a pulsatile release pattern, which triggers the anterior pituitary gland to secrete follicle-stimulating hormone (FSH) and luteinizing hormone (LH). The frequency and amplitude of GnRH pulses vary across the menstrual cycle, with faster pulses favoring LH release and slower pulses favoring FSH release.
01:22Birth Control Methods
Vasectomy is a surgical form of male sterilization that involves severing and sealing the vasa deferentia, preventing sperm from mixing with semen during ejaculation. Because a vasectomy does not impact the testes' ability to produce testosterone, hormone levels, libido, and sexual function generally remain unchanged. While vasectomy is highly effective in preventing pregnancy, with a success rate near 99.85%, rare cases of recanalization (spontaneous reconnection) can occur. Although vasectomy...
01:20Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
01:29Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...